Literature DB >> 23167659

The genetics of type 2 diabetes and its clinical relevance.

A Pal1, M I McCarthy.   

Abstract

The increasing worldwide prevalence of type 2 diabetes (T2D) motivates efforts to use genetics to define key pathways involved in disease predisposition, and thereby to improve management of the disease. Research over the past 5 years has taken the total number of genetic loci implicated in T2D susceptibility beyond 60, and the emphasis is now shifting to the translation of these genetic insights into clinical value. Clinical translation may flow from the identification of novel therapeutic targets, but opportunities also exist with respect to individual prediction, diagnostic biomarkers and therapeutic optimization. To date, the main clinical impact has been seen for relatively rare, monogenic forms of diabetes rather than common T2D. However, the advent of high throughput sequencing approaches may herald discovery of rare and low frequency variants that offer greater translational potential.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23167659     DOI: 10.1111/cge.12055

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  21 in total

1.  Genetics of type 2 diabetes.

Authors:  Omar Ali
Journal:  World J Diabetes       Date:  2013-08-15

Review 2.  The potential of novel biomarkers to improve risk prediction of type 2 diabetes.

Authors:  Christian Herder; Bernd Kowall; Adam G Tabak; Wolfgang Rathmann
Journal:  Diabetologia       Date:  2014-01       Impact factor: 10.122

3.  Genomic risk score provides predictive performance for type 2 diabetes in the UK biobank.

Authors:  Xiaolu Chen; Congcong Liu; Shucheng Si; Yunxia Li; Wenchao Li; Tonghui Yuan; Fuzhong Xue
Journal:  Acta Diabetol       Date:  2021-01-03       Impact factor: 4.280

Review 4.  Metabolomics in human type 2 diabetes research.

Authors:  Jingyi Lu; Guoxiang Xie; Weiping Jia; Wei Jia
Journal:  Front Med       Date:  2013-02-02       Impact factor: 4.592

Review 5.  β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  World J Diabetes       Date:  2015-02-15

6.  The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) plays a central role in insulin signaling and the Golgi/endosomes protein network.

Authors:  Martial Boutchueng-Djidjou; Gabriel Collard-Simard; Suzanne Fortier; Sébastien S Hébert; Isabelle Kelly; Christian R Landry; Robert L Faure
Journal:  Mol Cell Proteomics       Date:  2015-02-16       Impact factor: 5.911

7.  β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.

Authors:  Philippe A Halban; Kenneth S Polonsky; Donald W Bowden; Meredith A Hawkins; Charlotte Ling; Kieren J Mather; Alvin C Powers; Christopher J Rhodes; Lori Sussel; Gordon C Weir
Journal:  J Clin Endocrinol Metab       Date:  2014-04-08       Impact factor: 5.958

8.  Ankyrin-B metabolic syndrome combines age-dependent adiposity with pancreatic β cell insufficiency.

Authors:  Damaris N Lorenzo; Jane A Healy; Janell Hostettler; Jonathan Davis; Jiayu Yang; Chao Wang; Hans Ewald Hohmeier; Mingjie Zhang; Vann Bennett
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

Review 9.  Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.

Authors:  Harald Staiger; Elke Schaeffeler; Matthias Schwab; Hans-Ulrich Häring
Journal:  Rev Diabet Stud       Date:  2016-02-10

10.  KCNQ1 common genetic variant and type 2 diabetes mellitus risk.

Authors:  Taraneh Erfani; Negar Sarhangi; Mahdi Afshari; Davood Abbasi; Hamid Reza Aghaei Meybodi; Mandana Hasanzad
Journal:  J Diabetes Metab Disord       Date:  2019-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.